|
2005/OB/27
|
OXFORD BIOMEDICA
ANNOUNCES APPOINTMENT OF CHIEF MEDICAL OFFICER
Oxford
BioMedica (LSE:OXB.L), the leading gene therapy company, today
announces that Dr Mike McDonald has joined the Company as
Chief Medical Officer. He will have primary responsibility
for the Company’s clinical development activities and
regulatory affairs.
Mike brings over
20 years of experience in clinical drug development and regulatory
leadership. He joins from Seattle Genetics, a US based biotechnology
company, where he was Chief Medical Officer. Mike has spent
nine years with Eli Lilly serving as Worldwide Vice President,
Clinical Research and Medical Affairs, and was previously
at SmithKline Beecham for seven years where he was involved
in worldwide clinical development, regulatory management and
a member of the pharmaceutical development strategy committee.
From these positions Dr McDonald contributed to the successful
registration and commercialisation of many important pharmaceuticals.
He received his medical degree from Edinburgh University,
he is a member of the Royal College of Physicians in London,
holds a Diploma in Pharmaceutical Medicine and is a Fellow
of the Faculty of Pharmaceutical Physicians.
Commenting on the
appointment, Professor Alan Kingsman, Chief Executive of Oxford
BioMedica, said: "We are delighted that Mike McDonald
is joining the senior management team. As our lead programmes
advance and clinical activity expands, we welcome the considerable
experience that he brings."
-
ends -
Return to the News
|
|
Notes
| 1. |
Oxford
BioMedica |
|
Oxford BioMedica (LSE: OXB) is a biopharmaceutical
company specialising in the development
of novel gene-based therapeutics with a
focus on the areas of oncology and neurotherapy.
The Company was established in 1995 as a
spin out from Oxford University, and is
listed on the London Stock Exchange.
Oxford
BioMedica has core expertise in gene delivery,
as well as in-house clinical, regulatory
and manufacturing know-how. In oncology,
the pipeline includes an immunotherapy and
a gene therapy in multiple Phase II trials,
and a preclinical targeted antibody therapy
in collaboration with Wyeth. In neurotherapy,
the Company’s lead product is a gene
therapy for Parkinson’s disease, which
is expected to enter clinical trials in
2006, and four further preclinical candidates.
The Company is underpinned by over 80 patent
families, which represent one of the broadest
patent estates in the field.
The
Company has a staff of approximately 65
split between its main facilities in Oxford
and its wholly owned subsidiary, BioMedica
Inc, in San Diego, California. Oxford BioMedica
has corporate collaborations with Wyeth,
Intervet, Viragen, MolMed and Kiadis; and
has licensed technology to a number of companies
including Merck & Co, Biogen Idec and
Pfizer.
|
| |
|
For
further information please contact:
|
|
|
Oxford BioMedica plc
Professor Alan
Kingsman, Chief Executive |
Tel: +44 (0)1865 783 000 |
|
City/Financial
Enquiries
Lisa
Baderoon/Mark
Court/Mary-Jane
Johnson
Buchanan Communications |
Tel: +44 (0)20 7466 5000
|
Scientific/Trade
Press Enquiries
Sue
Charles, Katja
Stout, Ashley
Lilly
College Hill - Life Sciences |
Tel:
+44 (0)20 7886 8150 |
|
|
|
|
|
Top
of page
Website by College Hill - Life Sciences
|
| |
|
|
